$BFNH

BIOFORCE NANOSCIENCES HOLDINGS, INC.

CIK:0001310488|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Sales
Cost of Sales
Gross Profit
Operating Expenses
Board of Directors Compensation	143,750	105,750	249,500	211,500
General and Administrative	118,580	17,031	130,563	44,738
Total Expenses	262,330	122,781	380,063	256,238
Loss from Operations Before Other Income and (Expense)	(262,330)	(122,781)	(380,063)	(256,238)
Other Income and (Expense)
Forgiveness of Debt	502,373		502,373
Legal Settlement			15,322
Loss on Liability Settlement	(1,361)		(1,361)	(802,000)
Total Other Income and (Expense)	501,012		516,334	(802,000)
Net Income (Loss) for the Period	$ 238,682	$ (122,781)	$ 136,271	$ (1,058,238)
Weighted Average Number of Common Shares - Basic	33,544,161	33,521,755	33,532,896	32,887,777
Weighted Average Number of Common Shares - Diluted	33,544,161	33,521,755	33,532,896	32,887,777
Net Loss for the Period Per Common Shares - Basic	$ 0.01	$ (0.00)	$ 0.00	$ (0.03)
Net Loss for the Period Per Common Shares - Diluted	$ 0.01	$ (0.00)	$ 0.00	$ (0.03)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows from Operating Activities
Net Income (Loss) for the Period	$ 136,271	$ (1,058,238)
Adjustments to reconcile net income (loss) for the period to net cash
Board of Directors' Fees Transferred to Stock Payable	155,000
Forgiveness of Debt	(502,373)
Forgiveness of Accounts Payable	(2,895)
Consulting Fees to be Paid with Stock Payable	68,750
Interest Expense Paid with Common Stock	1,000
Land Lease Expense Gifted by Shareholder	7,485
Legal Fees to be Paid with Stock Payable	22,917
Loss on Liability Settlement	1,361	802,000
Changes in Assets and Liabilities:
Accounts Payable and Accrued Expenses	3,342	1,630
Accrued Board of Directors Compensation	89,250	211,500
Net Cash Flows Used In Operating Activities	(19,892)	(43,108)
Cash Flows from Investing Activities
Cash Flows from Financing Activities
Capital Contribution	2,000
Proceeds from Related Parties	17,413	43,151
Net Cash Flows Provided by Financing Activities	19,413	43,151
Net Change in Cash	(479)	43
Cash - Beginning of the Period	786	862
Cash - End of the Period	307	905
Cash Paid During the Period for:
Interest
Income Taxes

CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets
Cash	$ 307	$ 786
Prepaid Expenses	2,153,243
Total Current Assets	2,153,550	786
Capital Land Leases	234,525	786
Total Assets	2,388,075	786
Current Liabilities
Accounts Payable and Accrued Expenses	12,284	11,836
Accrued Board of Directors Compensation	21,750	506,203
Due to Related Parties	50,733	101,290
Total Current Liabilities	84,767	619,329
Total Liabilities	84,767	619,329
Stockholders' Equity (Deficit)
Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 33,549,005 and 33,521,755 Issued and Outstanding, Respectively	33,549	33,522
Additional Paid-In-Capital	162,061,305	161,760,052
Stock Payable	2,484,300
Accumulated Deficit	(162,275,846)	(162,412,117)
Total Stockholders' Equity (Deficit)	2,303,308	(618,543)
Total Liabilities and Stockholders' Equity (Deficit)	$ 2,388,075	$ 786